Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Paxlovid by Year
Paxlovid (nirmatrelvir/ritonavir oral COVID-19 treatment) — Worldwide revenues ($M) ($M)
Pfizer Paxlovid: $2,362M in FY2025, down 58.7% from a year earlier.
Latest, FY2025
2,362
Period ended Dec 31, 2025
Change on a year earlier
-58.7%
5,716 in FY2024
History
7 years
Since FY2019
Sources
6
Documents cited below
Where the FY2025 figure comes from
“|| Paxlovid (d) | 2,362 | 5,716 | (59%) | (59%) | 1,891 | 4,616 | (59%) | 470 | 1,100 | (57%) | (57%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Paxlovid (nirmatrelvir/ritonavir oral COVID-19 treatment) — Worldwide revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,362 | -58.7% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 5,716 | +346.9% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 1,279 | -60.5% | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 3,237 | +4,159.2% | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2021 | Dec 31, 2021 | 76 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| FY2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2023-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-24) ↗ |
Breakdown
What makes up paxlovid
- Paxlovid (nirmatrelvir/ritonavir oral COVID-19 treatment) — U.S. revenues ($M)1,891 · FY2025
- Paxlovid (nirmatrelvir/ritonavir oral COVID-19 treatment) — International revenues ($M)470 · FY2025
- Paxlovid (nirmatrelvir/ritonavir oral COVID-19 treatment) — Worldwide reported YoY (%)-59.0% · FY2025
- Paxlovid (nirmatrelvir/ritonavir oral COVID-19 treatment) — Worldwide operational (constant-currency) YoY (%)-59.0% · FY2025
Cite this data
StockData. (2026). Pfizer Paxlovid ($M), annual FY2019–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/paxlovid-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.